BioCentury
ARTICLE | Clinical News

Velcade bortezomib regulatory update

November 8, 2004 8:00 AM UTC

FDA granted Fast Track designation to Velcade to treat relapsed and refractory mantle cell lymphoma, a form of non-hodgkin's lymphoma (NHL). The small molecule dipeptide boronic acid proteasome inhibi...